UGT2B17
| UGT2B17 | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifikatori | |||||||||||||||||||||||||
| Alijasi | UGT2B17 | ||||||||||||||||||||||||
| Spoljašnji ID | OMIM: 601903 MGI: 1919023 HomoloGene: 68144 GeneCards: UGT2B17 | ||||||||||||||||||||||||
| |||||||||||||||||||||||||
| |||||||||||||||||||||||||
| Ortolozi | |||||||||||||||||||||||||
| Vrste | Čovek | Miš | |||||||||||||||||||||||
| Entrez | |||||||||||||||||||||||||
| Ensembl | |||||||||||||||||||||||||
| UniProt | |||||||||||||||||||||||||
| RefSeq (mRNA) | |||||||||||||||||||||||||
| RefSeq (protein) | |||||||||||||||||||||||||
| Location (UCSC) | n/a | Chr 5: 87.06 – 87.07 Mb | |||||||||||||||||||||||
| PubMed search | [2] | [3] | |||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||
| |||||||||||||||||||||||||
UDP-glukuronoziltransferaza 2B17 je enzim koji je kod ljudi kodiran genom UGT2B17.[4][5]
UGT2B17 pripada porodici UDP-glukuronoziltransferaza (UGT; EC 2.4.1.17), enzima koji katalizuju prenos glukuronske kiseline iz uridin difosfoglukuronske kiseline na različite supstrate, uključujući steroidne hormone.[5] Takođe metabolizuje 3-hidroksikotinin, koji je manje zastupljeni metabolit nikotina.[6]
Reference[уреди | уреди извор]
- ^ а б в GRCm38: Ensembl release 89: ENSMUSG00000035836 - Ensembl, May 2017
- ^ „Human PubMed Reference:”. National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ „Mouse PubMed Reference:”. National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Beaulieu M, Levesque E, Hum DW, Belanger A (новембар 1996). „Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids”. J Biol Chem. 271 (37): 22855—62. PMID 8798464. doi:10.1074/jbc.271.37.22855
.
- ^ а б „Entrez Gene: UGT2B17 UDP glucuronosyltransferase 2 family, polypeptide B17”.
- ^ Chen G, Giambrone NE, Dluzen DF, Muscat JE, Berg A, Gallagher CJ, Lazarus P (октобар 2010). „Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms”. Cancer Research. 70 (19): 7543—52. PMC 2998997 . PMID 20876810. doi:10.1158/0008-5472.CAN-09-4582.
Literatura[уреди | уреди извор]
- Chung LW, Coffey DS (1978). „Androgen glucuronide. II. Differences in its formation by human normal and benign hyperplastic prostates.”. Investigative Urology. 15 (5): 385—8. PMID 76619.
- Moghissi E, Ablan F, Horton R (1984). „Origin of plasma androstanediol glucuronide in men.”. J. Clin. Endocrinol. Metab. 59 (3): 417—21. PMID 6746859. doi:10.1210/jcem-59-3-417.
- Beaulieu M, Lévesque E, Tchernof A, et al. (1997). „Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme.”. DNA Cell Biol. 16 (10): 1143—54. PMID 9364925. doi:10.1089/dna.1997.16.1143.
- Collier AC, Ganley NA, Tingle MD, et al. (2002). „UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term.”. Biochem. Pharmacol. 63 (3): 409—19. PMID 11853692. doi:10.1016/S0006-2952(01)00890-5.
- Chouinard S, Pelletier G, Bélanger A, Barbier O (2005). „Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium.”. Endocr. Res. 30 (4): 717—25. PMID 15666817. S2CID 10971899. doi:10.1081/ERC-200044014.
- Lazarus P, Zheng Y, Aaron Runkle E, et al. (2006). „Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes.”. Pharmacogenet. Genomics. 15 (11): 769—78. PMID 16220109. S2CID 10171438. doi:10.1097/01.fpc.0000175596.52443.ef.
- Jakobsson J, Ekström L, Inotsume N, et al. (2006). „Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism.”. J. Clin. Endocrinol. Metab. 91 (2): 687—93. PMID 16332934. doi:10.1210/jc.2005-1643 .
- Park J, Chen L, Ratnashinge L, et al. (2006). „Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men.”. Cancer Epidemiol. Biomarkers Prev. 15 (8): 1473—8. PMID 16896035. doi:10.1158/1055-9965.EPI-06-0141 .
- Gallagher CJ, Muscat JE, Hicks AN, et al. (2007). „The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer.”. Cancer Epidemiol. Biomarkers Prev. 16 (4): 823—8. PMID 17416778. doi:10.1158/1055-9965.EPI-06-0823 .
- Park JY, Tanner JP, Sellers TA, et al. (2007). „Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk.”. Urology. 70 (2): 374—9. PMID 17826523. doi:10.1016/j.urology.2007.03.001.
- Chouinard S, Barbier O, Bélanger A (2008). „UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells.”. J. Biol. Chem. 282 (46): 33466—74. PMID 17848572. doi:10.1074/jbc.M703370200 .